[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367189-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367189-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advancing-glioblastoma-research-with-innovative-brain-organoid-based-models-review","Advancing Glioblastoma Research with Innovative Brain Organoid-Based Models - review","","Glioblastoma (GBM) is a rare yet highly aggressive brain cancer marked by rapid growth, invasion, and resistance to standard therapies. Despite advances in molecular and cellular understanding, treatment remains difficult due to tumor heterogeneity and a complex tumor microenvironment. To overcome model limitations, researchers increasingly refine preclinical systems using human-origin cells, advanced genetics, and stem cell bioengineering, including brain organoid-based models. This review summarizes organoid model preparation and applications to deepen GBM biology knowledge and support novel therapeutic development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advancing-glioblastoma-research-with-innovative-brain-organoid-based-models-review/367189/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advancing-glioblastoma-research-with-innovative-brain-organoid-based-models-review/367189.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is glioblastoma difficult to treat despite standard therapies?","Question",{"text":63,"@type":64},"Standard care (maximal safe surgery, radiotherapy, and temozolomide) yields only modest survival benefits, while frequent rapid relapses and resistant residual cells limit long-term success.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What factors contribute to poor GBM therapeutic outcomes?",{"text":68,"@type":64},"Outcomes are attributed to the blood–brain barrier, highly invasive tumor behavior, and prominent tumor heterogeneity within the complex tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"How do brain organoid-based models help advance GBM research?",{"text":72,"@type":64},"Brain organoid models better capture GBM complexity preclinically by incorporating human-origin cells, advanced genetic approaches, and stem cell-based bioengineering, supporting investigation of biology and novel therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367189,1790459714,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nAdvancing Glioblastoma Research with Innovative Brain Organoid-Based Models  \nCátia D. Correia 1,2, Sofia M. Calado 1,3, Alexandra Matos 1, Filipa Esteves 1,2, Ana Luísa De Sousa-Coelho 1,4, Marco A. Campinho 1,2 and Mónica T. Fernandes 1,4, *  \nAcademic Editor: Alexander  \nE. Kalyuzhny  \nReceived: 12 January 2025  \nRevised: 6 February 2025  \nAccepted: 14 February 2025  \nPublished: 16 February 2025  \nCitation: Correia, C.D.; Calado, S.M.; Matos, A.; Esteves, F.; De SousaCoelho, A.L.; Campinho, M.A.; Fernandes, M.T. Advancing Glioblastoma Research with Innovative Brain Organoid-Based Models. Cells 2025, 14, 292 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells14040292  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve, Campus de Gambelas,  \n8005-139 Faro, Portugal; [a57384@ualg.pt](a57384@ualg.pt) (C.D.C.); [sofia.am.calado@uac.pt](sofia.am.calado@uac.pt) (S.M.C.);  \n[macampinho@ualg.pt](macampinho@ualg.pt) (M.A.C.)  \n2 Faculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve (UAlg), Campus de Gambelas, 8005-139 Faro, Portugal  \n3 Faculdade de Ciências e Tecnologia (FCT), Universidade dos Açores (UAc), 9500-321 Ponta Delgada, Portugal  \n4 Escola Superior de Saúde (ESS), Universidade do Algarve (UAlg), Campus de Gambelas, 8005-139 Faro, Portugal  \n* [Correspondence: mafernandes@ualg.pt](Correspondence: mafernandes@ualg.pt)  \nAbstract: Glioblastoma (GBM) is a relatively rare but highly aggressive form of brain cancer characterized by rapid growth, invasiveness, and resistance to standard therapies. Despite significant progress in understanding its molecular and cellular mechanisms, GBM remains one of the most challenging cancers to treat due to its high heterogeneity and complex tumor microenvironment. To address these obstacles, researchers have employed a range of models, including in vitro cell cultures and in vivo animal models, but these often fail to replicate the complexity of GBM. As a result, there has been a growing focus on refining these models by incorporating human-origin cells, along with advanced genetic techniques and stem cell-based bioengineering approaches. In this context, a variety of GBM models based on brain organoids were developed and confirmed to be clinically relevant and are contributing to the advancement of GBM research at the preclinical level. This review explores the preparation and use of brain organoid-based models to deepen our understanding of GBM biology and to explore novel therapeutic approaches. These innovative models hold significant promise for improving our ability to study this deadly cancer and for advancing the development of more effective treatments.  \nKeywords: glioblastoma; brain organoids; disease models; drug discovery; human stem cells; tumor heterogeneity; invasion; microenvironment  \n1. Enduring Challenges in Glioblastoma Research and Therapy  \nIn adult and elderly patients, glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor [1–3] . It is classified among gliomas, cancers originating from glial cells or their precursors in the nervous system, specifically as a grade 4 astrocytoma with wild-type isocitrate dehydrogenase 1 or 2 (IDH1/2) alleles. These are usually associated with other features, such as the combined gain of chromosome 7 and loss of chromosome 10 (+7/−10), telomerase reverse transcriptase (TERT) promoter mutations, epidermal growth factor receptor (EGFR) gene amplification, necrosis, and microvascular proliferation [4] .  \nGBM is considered one of the most challenging cancers to treat. Its standard ","cbCaifopuMdzM9A4","https://ap.wps.com/l/cbCaifopuMdzM9A4","pdf",843428,"English","# Abstract\n# Enduring Challenges in Glioblastoma Research and Therapy","[{\"question\":\"Why is glioblastoma difficult to treat despite standard therapies?\",\"answer\":\"Standard care (maximal safe surgery, radiotherapy, and temozolomide) yields only modest survival benefits, while frequent rapid relapses and resistant residual cells limit long-term success.\"},{\"question\":\"What factors contribute to poor GBM therapeutic outcomes?\",\"answer\":\"Outcomes are attributed to the blood–brain barrier, highly invasive tumor behavior, and prominent tumor heterogeneity within the complex tumor microenvironment.\"},{\"question\":\"How do brain organoid-based models help advance GBM research?\",\"answer\":\"Brain organoid models better capture GBM complexity preclinically by incorporating human-origin cells, advanced genetic approaches, and stem cell-based bioengineering, supporting investigation of biology and novel therapies.\"}]","Advancing Glioblastoma Research with Innovative Brain Organoid-Based Models - review | PDF",1790169666,76,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a358560f6101fb0a1bbdef6d71ab6001.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/789b4602d5d6f3e70d6161d4fb669c0d.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/513f98c300db67c04560ebb6bc9b622f.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9f03283901a38fd5b0c74f2189cfd91.webp",980,1385]